Guidelines Directed Optics for Non-Obstructive Diseases

The majority of patients in our original wise publications had non-obstructed atherosclerotic plaque well over 80%. And so we did several pharmacologic probe trials as well testing things that we had on the shelf to repurpose for vascular dysfunction called coronary microvascular dysfunction. The Swedes, I'll just conclude the Swedes had a my NOCA bat trial where they were randomizing them to beta blocker. We've continued to recruit despite the pandemic and hope that we'll have an answer about whether or not something just practical like that could improve outcomes.